The U.S. Food and Drug Administration (FDA) approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 6 to 11, who have two copies of the F508del mutation.
- About the CF Foundation
- Public Policy
- Drug Pipeline
- CFTR Modulators
- Get Involved
- Our Research Approach
- Clinical Trials
- Health Care Reform
- North American CF Conference
- Care Centers
- Our Advocacy Work
- Patient Assistance
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Patient Registry
- Infection Prevention and Control
- Lung Transplantation
- In the Spotlight
- Coronavirus (COVID-19)
- Diversity, Equity, and Inclusion
- Intro to CF
- Clinician Resources
- Great Strides
- In Memoriam
- Adult Care
- Care Team
- CF-Related Complications
- CF Related Health Conditions
- Fertility and Reproductive Health
- Researcher Resources
- (-) Genetic Therapies
The European Commission has approved the cystic fibrosis drug Orkambi® for people with two copies of the F508del mutation ages 12 and older in the European Union.
Today we received the exciting news that the U.S. Food and Drug Administration has approved Orkambi for people with cystic fibrosis ages 12 and older who have two copies of the F508del gene mutation, the most common CF mutation.
The U.S. Food and Drug Administration (FDA) announced today that it has approved the use of ivacaftor (Kalydeco™) to treat people with cystic fibrosis ages 6 and older who have the R117H mutation.
Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $15 million research agreement with biopharmaceutical company Shire plc to support the development of a new cystic fibrosis treatment targeting the underlying cause of the disease.
Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation, announced it will extend funding for continued collaboration with Proteostasis Therapeutics, Inc., for the development of new therapies to treat the most common CF mutation, Delta F508.
The U.S. Food and Drug Administration announced today it has approved Kalydeco™ to treat people ages 6 and older who have one of eight additional cystic fibrosis mutations.
“For the first time in over a decade, a striking silence fills the Cheevers' barn-style home,” begins a story in the September issue of the science magazine Discover.
The European Commission has approved the use of the CF therapy Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.